Chengdu Yoluo Biotechnology

Chengdu Yoluo Biotechnology is a clinical-stage biotechnology company focused on developing innovative T-cell therapies for the treatment of solid tumors. The company utilizes its proprietary technology to develop CAR-T and TCR-T products that are specifically engineered to overcome the immunosuppressive barriers of the tumor microenvironment. Its lead program, YL-101, is a CAR-T therapy targeting GPC3 for hepatocellular carcinoma, which has entered clinical trials. Another key asset, YL-201, is a TCR-T therapy targeting NY-ESO-1 for various solid malignancies. Based in Chengdu, China, Yoluo Biotech leverages advanced gene editing and cell engineering platforms to enhance the persistence and efficacy of its therapeutic candidates. The company aims to provide curative cellular immunotherapies for cancer patients with limited treatment options.